Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ADO-5030
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Recipient : Adial Pharmaceuticals
Deal Size : $83.0 million
Deal Type : Agreement
Adial Pharma gets Milestone Payment from Adovate After Phase 1 Study Start
Details : Under the agreement, the ADO-5030 compound is being developed by Adovate as a potential first-line therapy for asthma.
Product Name : ADO-5030
Product Type : Other Small Molecule
Upfront Cash : $0.4 million
May 13, 2025
Lead Product(s) : ADO-5030
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Recipient : Adial Pharmaceuticals
Deal Size : $83.0 million
Deal Type : Agreement